Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma
NCT04065152Phase 2Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2021
- Primary completion
- Feb 2023
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of talimogene laherparepvec in Kaposi sarcoma (KS), sponsored by Assistance publique - Hôpitaux de Paris. Status: unknown.
02
Drugs
talimogene laherparepvec
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT04065152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04065152.